JPMorgan Chase & Co. Issues Pessimistic Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its price target lowered by research analysts at JPMorgan Chase & Co. from $9.00 to $7.00 in a report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the health services provider’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 32.95% from the company’s previous close.

A number of other research analysts have also recently issued reports on TDOC. Barclays assumed coverage on Teladoc Health in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price objective on the stock. Piper Sandler reissued an “overweight” rating and issued a $9.00 target price (down from $12.00) on shares of Teladoc Health in a research note on Thursday, February 26th. Canaccord Genuity Group dropped their target price on Teladoc Health from $12.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, February 26th. BMO Capital Markets decreased their price target on Teladoc Health from $8.00 to $5.00 and set a “market perform” rating on the stock in a research note on Thursday, February 26th. Finally, Citigroup lowered their price objective on Teladoc Health from $9.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, March 3rd. Six investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Teladoc Health has an average rating of “Hold” and a consensus target price of $7.72.

Teladoc Health Trading Down 1.8%

Shares of TDOC traded down $0.10 during mid-day trading on Friday, reaching $5.27. The company’s stock had a trading volume of 1,212,790 shares, compared to its average volume of 6,819,761. The stock has a market cap of $939.28 million, a PE ratio of -4.64 and a beta of 2.13. The company has a current ratio of 2.77, a quick ratio of 2.67 and a debt-to-equity ratio of 0.72. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.77. The company’s fifty day moving average price is $5.66 and its two-hundred day moving average price is $7.07.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. The company had revenue of $642.27 million for the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. The firm’s quarterly revenue was up .3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, analysts predict that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insider Activity at Teladoc Health

In other news, CEO Charles Divita III sold 27,731 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the sale, the chief executive officer directly owned 364,784 shares in the company, valued at approximately $2,002,664.16. This represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC lifted its holdings in Teladoc Health by 236.6% in the 4th quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider’s stock worth $264,000 after buying an additional 26,494 shares during the period. Alpine Global Management LLC purchased a new position in shares of Teladoc Health during the fourth quarter valued at approximately $187,000. Virtu Financial LLC bought a new position in shares of Teladoc Health during the fourth quarter valued at approximately $854,000. Mackenzie Financial Corp raised its holdings in shares of Teladoc Health by 38.6% during the fourth quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider’s stock valued at $1,157,000 after acquiring an additional 46,090 shares in the last quarter. Finally, Empowered Funds LLC lifted its stake in Teladoc Health by 1.9% in the fourth quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider’s stock worth $5,196,000 after acquiring an additional 14,029 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Key Headlines Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Zacks Research revised a wide set of near‑ and medium‑term EPS estimates upward (notably FY2026 to -$0.99 from -$1.11 and FY2027 to -$1.02 from -$1.10), improving the company’s profitability trajectory and reducing expected losses. This helps justify recent analyst upgrade interest.
• Positive Sentiment: Deutsche Bank upgraded TDOC to a buy, signaling growing institutional conviction after Teladoc’s BetterHelp strength, earnings beat and strategic AI/international plans. Such upgrades can attract new flows and support the stock. Deutsche Bank upgrade
• Positive Sentiment: Coverage pieces highlight that analyst upgrades and an earnings surprise have put Teladoc back on investors’ radar, emphasizing BetterHelp, AI initiatives and international expansion as potential growth drivers that could re-rate the valuation if execution continues. Valuation/analysis article
• Neutral Sentiment: Recent Zacks quarter-to-quarter estimate tweaks include a very small downgrade for Q3 2027 (from -$0.25 to -$0.26) — a minor variance within a broader pattern of upward revisions; not likely to move the stock materially by itself.
• Negative Sentiment: Teladoc’s CEO, Charles Divita III, sold 27,731 shares at about $5.49. Insider sales can be perceived negatively by the market even if they are routine or for personal reasons. SEC Form 4
• Negative Sentiment: Short‑term price weakness and below‑average intraday volume raise the risk of limited buying support; the stock remains well below its 200‑day moving average, which can weigh on investor confidence.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.